- A class action lawsuit has been filed against **Unicycive Therapeutics, Inc. (UNCY)** and certain officers, alleging materially false and misleading statements regarding the company's ability to satisfy **FDA manufacturing compliance requirements** for its oxylanthanum carbonate (OLC) New Drug Application (NDA).  **[1766140_20251013DC96232:0]** 
- The class period for the lawsuit is between **March 29, 2024, and June 27, 2025**, with investors having until **October 14, 2025**, to seek appointment as Lead Plaintiff.  **[1766140_20251013DC96232:0]** 
- Unicycive's stock price fell **40.89%** to **$5.32 per share** on **June 10, 2025**, after the FDA identified cGMP deficiencies, and an additional **29.85%** to **$4.77 per share** on **June 30, 2025**, following a Complete Response Letter (CRL) for the OLC NDA.  **[1766140_20251013DC96232:0]**

Unicycive Therapeutics faces class action lawsuit

- Faruqi & Faruqi, LLP is investigating **Unicycive Therapeutics** (NASDAQ: UNCY) for potential federal securities law violations, with a lead plaintiff deadline of **October 14, 2025**.  **[1766140_f79f3b40dfcb40c481988d7e293574c7_0]** 
- The complaint alleges that Unicycive overstated its ability to meet **FDA manufacturing compliance requirements** and the regulatory prospects of its OLC NDA.  **[1766140_f79f3b40dfcb40c481988d7e293574c7_0]** 
- Unicycive's stock price experienced significant drops: **40.89%** on **June 10, 2025**, and an additional **29.85%** on **June 30, 2025**, following disclosures of **FDA-identified cGMP deficiencies** and a subsequent **Complete Response Letter** for the OLC NDA.  **[1766140_f79f3b40dfcb40c481988d7e293574c7_0]** **[1766140_f79f3b40dfcb40c481988d7e293574c7_1]** 
- Investors who incurred losses between **March 29, 2024, and June 27, 2025**, are encouraged to contact the law firm.  **[1766140_f79f3b40dfcb40c481988d7e293574c7_0]**

Unicycive Therapeutics Faces Securities Class Action Lawsuit

- Faruqi & Faruqi, LLP is investigating **Unicycive Therapeutics** for potential federal securities law violations, alleging the company made false and/or misleading statements regarding its readiness to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA.  **[1766140_ef8e1b0437c74eec96429bb064599ffb_1]** 
- Investors who suffered losses in Unicycive between **March 29, 2024, and June 27, 2025**, are encouraged to contact the firm, with the deadline to seek the role of lead plaintiff in the federal securities class action set for **October 14, 2025**.  **[1766140_ef8e1b0437c74eec96429bb064599ffb_0]** **[1766140_ef8e1b0437c74eec96429bb064599ffb_1]** 
- The investigation follows significant stock price declines: a **40.89%** drop on **June 10, 2025**, after Unicycive disclosed FDA-identified cGMP deficiencies at a third-party manufacturing vendor, and a further **29.85%** fall on **June 30, 2025**, when the FDA issued a Complete Response Letter for the OLC NDA citing these deficiencies.  **[1766140_ef8e1b0437c74eec96429bb064599ffb_1]**

Faruqi & Faruqi Investigates Unicycive Therapeutics for Securities Violations

- Faruqi & Faruqi, LLP is investigating **Unicycive Therapeutics (UNCY)** for alleged federal securities law violations, with a **October 14, 2025 deadline** for investors who purchased securities between **March 29, 2024, and June 27, 2025**, to seek lead plaintiff status.  **[1766140_20251010NY94633:0]** 
- The complaint alleges that Unicycive overstated its readiness to satisfy **FDA manufacturing compliance requirements** and the regulatory prospects of its **OLC NDA**.  **[1766140_20251010NY94633:0]** 
- Unicycive's stock price fell **40.89%** to **$5.32 per share** on **June 10, 2025**, after disclosing FDA cGMP deficiencies, and further dropped **29.85%** to **$4.77 per share** on **June 30, 2025**, following a Complete Response Letter for the OLC NDA.  **[1766140_20251010NY94633:0]**

Unicycive Therapeutics Faces Securities Class Action Investigation

- Pomerantz LLP has filed a class action lawsuit against **Unicycive Therapeutics, Inc. (UNCY)** and certain officers, covering the period from **March 29, 2024, to June 27, 2025**.  **[1766140_20251008DC93535:0]** 
- The lawsuit alleges that Unicycive made materially false and misleading statements regarding its readiness to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its **oxylanthanum carbonate (OLC) New Drug Application (NDA)**.  **[1766140_20251008DC93535:0]** 
- Unicycive's stock price fell **40.89%** on **June 10, 2025**, after the FDA identified cGMP deficiencies at a third-party manufacturer, and an additional **29.85%** on **June 30, 2025**, following a Complete Response Letter for the OLC NDA.  **[1766140_20251008DC93535:0]** 
- Investors who purchased Unicycive securities during the class period have until **October 14, 2025**, to seek appointment as Lead Plaintiff.  **[1766140_20251008DC93535:0]**

Unicycive Therapeutics Faces Class Action Lawsuit

- Faruqi & Faruqi, LLP is investigating **Unicycive Therapeutics** for potential federal securities law violations related to alleged false and/or misleading statements.  **[1766140_47ddca64db4d46a9ae82cc878146ae29_1]** 
- The investigation focuses on claims that the company overstated its readiness to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA.  **[1766140_47ddca64db4d46a9ae82cc878146ae29_1]** 
- On **June 10, 2025**, Unicycive's stock price fell **40.89%** after disclosing FDA-identified deficiencies in cGMP compliance at a third-party manufacturing vendor.  **[1766140_47ddca64db4d46a9ae82cc878146ae29_1]** 
- The stock price further declined by **29.85%** on **June 30, 2025**, following the FDA's Complete Response Letter for the OLC NDA, citing the previously identified cGMP deficiencies.  **[1766140_47ddca64db4d46a9ae82cc878146ae29_1]** 
- Investors who suffered losses between **March 29, 2024, and June 27, 2025**, are encouraged to contact the firm, with a **lead plaintiff deadline of October 14, 2025**.  **[1766140_47ddca64db4d46a9ae82cc878146ae29_0]** **[1766140_47ddca64db4d46a9ae82cc878146ae29_1]**

- Faruqi & Faruqi, LLP is investigating **Unicycive Therapeutics, Inc. (UNCY)**, and a federal securities class action has been filed against the company, alleging it made false and misleading statements regarding its readiness for FDA manufacturing compliance and the regulatory prospects of its OLC NDA.  **[1766140_c9c980c9a18d4028a98244e9fe33da9f_1]** 
- The investigation follows two significant stock price declines in **June 2025**: a **40.89% drop** on **June 10, 2025**, after Unicycive disclosed FDA-identified manufacturing deficiencies, and a **29.85% drop** on **June 30, 2025**, when the FDA issued a Complete Response Letter for the OLC NDA due to these issues.  **[1766140_c9c980c9a18d4028a98244e9fe33da9f_1]** 
- Investors who purchased UNCY securities between **March 29, 2024, and June 27, 2025**, and incurred losses are encouraged to contact the firm, with the deadline to seek lead plaintiff status set for **October 14, 2025**.  **[1766140_c9c980c9a18d4028a98244e9fe33da9f_0]** **[1766140_c9c980c9a18d4028a98244e9fe33da9f_1]**

Faruqi & Faruqi Investigates Unicycive Therapeutics Over Alleged Misleading Statements

- **Bragar Eagel & Squire, P.C.** has filed a class action lawsuit against **Unicycive Therapeutics, Inc. (UNCY)**.  **[1766140_5601d4860d8c4124a4f3c62851654498_0]** 
- The lawsuit covers investors who purchased Unicycive securities between **March 29, 2024, and June 27, 2025**.  **[1766140_5601d4860d8c4124a4f3c62851654498_0]** 
- Investors have until **October 14, 2025**, to apply to be appointed as lead plaintiff.  **[1766140_5601d4860d8c4124a4f3c62851654498_0]** 
- The complaint alleges Unicycive overstated its ability to meet **FDA manufacturing compliance requirements** for its oxylanthanum carbonate (OLC) New Drug Application.  **[1766140_5601d4860d8c4124a4f3c62851654498_0]** 
- Unicycive's stock price fell over **40%** on June 10, 2025, and an additional **30%** on June 30, 2025, following FDA announcements regarding manufacturing deficiencies and a Complete Response Letter.  **[1766140_5601d4860d8c4124a4f3c62851654498_0]**

- Faruqi & Faruqi, LLP is investigating Unicycive Therapeutics (UNCY) for potential federal securities law violations, encouraging investors who purchased securities between **March 29, 2024, and June 27, 2025**, to contact them.  **[1766140_20251003NY88558:0]** 
- The investigation alleges that Unicycive made false or misleading statements regarding its ability to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA.  **[1766140_20251003NY88558:0]** 
- Following disclosures of FDA manufacturing compliance deficiencies and a Complete Response Letter for the OLC NDA, Unicycive's stock price fell **40.89%** on **June 10, 2025**, and an additional **29.85%** on **June 30, 2025**.  **[1766140_20251003NY88558:0]** 
- The deadline for investors to seek the role of lead plaintiff in the class action lawsuit is **October 14, 2025**.  **[1766140_20251003NY88558:0]**

- Pomerantz LLP has filed a class action lawsuit against Unicycive Therapeutics, Inc. and certain officers.  **[1766140_20251003DC87777:0]** 
- The lawsuit covers the period between **March 29, 2024, and June 27, 2025**, alleging that defendants made materially false and misleading statements regarding the company's readiness and ability to satisfy FDA manufacturing compliance requirements for its oxylanthanum carbonate (OLC) New Drug Application (NDA).  **[1766140_20251003DC87777:0]** 
- Unicycive's stock price fell **40.89%** on June 10, 2025, after the company disclosed FDA identified deficiencies in cGMP compliance at a third-party manufacturing vendor, and further dropped **29.85%** on June 30, 2025, following a Complete Response Letter for the OLC NDA.  **[1766140_20251003DC87777:0]** 
- Investors who purchased Unicycive securities during the class period have until **October 14, 2025**, to apply to be appointed as Lead Plaintiff.  **[1766140_20251003DC87777:0]**